Skip to main navigation Skip to search Skip to main content

Unsupervised home spirometry versus supervised clinic spirometry: analysis of longitudinal participant-level data from the CLEAR trial in patients with bronchiectasis

  • Ryan McChrystal
  • , Rebecca H McLeese
  • , Brenda O’Neill
  • , Daniel F McAuley
  • , J Stuart Elborn
  • , Mike Clarke
  • , John Norrie
  • , Dermot Linden
  • , Jonathan Stewart
  • , Andrew Jackson
  • , William D-C Man
  • , Anthony De Soyza
  • , James D Chalmers
  • , Rohan Anand
  • , Fiona Copeland
  • , Judy M Bradley
  • Queen's University Belfast
  • Northern Ireland Clincial Trials Unit
  • Imperial College London
  • Newcastle University
  • University of Dundee

Research output: Contribution to journal › Article › peer-review

40 Downloads (Pure)

Abstract

Background: Lung function measurement is central to assessing disease severity and monitoring progression in bronchiectasis. Although home spirometry is convenient for remote monitoring, there is limited evidence for its performance. Aims: In an a priori defined substudy in the CLEAR trial (a multicentre, randomised, open-label study of hypertonic saline and carbocisteine versus usual care in bronchiectasis), we assessed the performance of home spirometry in adults with bronchiectasis using the PANACEA framework (seven domains: test Performance, disease mANAgement, Cost, patient Experience, clinician Experience, researcher Experience, and Access). Methods: Participants performed supervised ‘clinic’ spirometry at five visits and unsupervised ‘home’ spirometry weekly and during exacerbations over 52 weeks. Analyses evaluated agreement, longitudinal variation, changes in lung function across exacerbations, measurement quality, adherence and patient experience. Agreement was evaluated using Bland-Altman analysis; other outcomes were summarised descriptively. Results: 257 participants had home spirometry data. Clinic and home spirometry demonstrated close agreement, with a mean forced expiratory volume in 1 s (FEV1) difference of 20 mL (95% CI −130 to 170). Variability decreased over time (coefficient of variation 12.25% to 8.81%). Among 462 exacerbations, 195 had spirometry data within 7 days of exacerbation start/end dates. A >100 mL decline in FEV1 occurred in 48% of exacerbations; 35% returned to within 100 mL of pre-exacerbation stable values by exacerbation end. Most spirometry sessions met American Thoracic Society/European Respiratory Society quality criteria, adherence declined over time while patient experience was generally positive. Conclusion: Home spirometry demonstrates good agreement with clinic spirometry, with variability between measurements decreasing over time. Home spirometry detected changes in lung function across exacerbations, although variability may limit interpretation at the individual patient level. With appropriate patient support to maintain adherence, home spirometry has potential as a tool for remote monitoring and decentralised clinical trials in bronchiectasis.
Original languageEnglish
Article numberthorax-2026-225189
Pages (from-to)1-9
Number of pages9
JournalThorax
Early online date5 Aug 2026
DOIs
Publication statusPublished online - 5 Aug 2026

Bibliographical note

© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

Rights Retention Statement

This Author Accepted Manuscript has been made open access under a Creative Commons Attribution 4.0 International licence (CC BY 4.0) under the terms of Ulster University Rights Retention Policy for Scholarly Works. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

Data Availability Statement

Data are available on reasonable request.

Funding

The CLEAR trial was supported by a grant (15/100/01) from the National Institute for Health and Care Research Health Technology Assessment Programme, by the Belfast Health and Social Care Trust Charitable Funds and by PARI GmbH, which provided spirometers for patient use (mySpiroSense) and clinician use (SpiroSense Pro), laptop computers equipped with spirometry software (SpiroSense PC) and access to PARI’s software, PARItrack Webportal.

Funder number
15/100/01

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Bronchiectasis
    • Respiratory Function Tests

    Fingerprint

    Dive into the research topics of 'Unsupervised home spirometry versus supervised clinic spirometry: analysis of longitudinal participant-level data from the CLEAR trial in patients with bronchiectasis'. Together they form a unique fingerprint.

    Cite this